Novo Nordisk and Eli Lilly Could Have a Big Rival in the GLP-1 Market in a Few Years

By Yahoo! Finance | Aug 18, 2024 at 06:31 AM EST

Novo Nordisk and Eli Lilly lead the weight loss market with GLP-1 drugs, but face competition from Roche. Roche's upcoming GLP-1 weight loss drugs show promise, potentially challenging the market leaders. Investors should monitor Roche's development in the competitive landscape.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.